Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-centre, randomised, double-blind, placebo-controlled, parallel group study of the efficacy, safety and tolerability of perampanel in levodopa treated Parkinson's disease patients with motor fluctuations.

Next Previous
X
Search
Trial Profile

A multi-centre, randomised, double-blind, placebo-controlled, parallel group study of the efficacy, safety and tolerability of perampanel in levodopa treated Parkinson's disease patients with motor fluctuations.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perampanel (Primary)
  • Indications Parkinson's disease
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Eisai Co Ltd

    • Most Recent Events

    • 19 Oct 2012 Planned number of patients changed from 900 to 1260.
    • 09 Dec 2011 Primary endpoint 'Off-time' has not been met.
    • 10 Apr 2008 Status changed from recruiting to completed as reported by Eisai.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top